TN2019000004A1 - Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens. - Google Patents

Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.

Info

Publication number
TN2019000004A1
TN2019000004A1 TNP/2019/000004A TN2019000004A TN2019000004A1 TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1 TN 2019000004 A TN2019000004 A TN 2019000004A TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1
Authority
TN
Tunisia
Prior art keywords
cancer
treatment
formula
vita
major
Prior art date
Application number
TNP/2019/000004A
Other languages
English (en)
Inventor
Ghidhaoui Abir
Original Assignee
Ghidhaoui Abir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghidhaoui Abir filed Critical Ghidhaoui Abir
Priority to TNP/2019/000004A priority Critical patent/TN2019000004A1/fr
Priority to PCT/TN2019/000008 priority patent/WO2020145905A1/fr
Publication of TN2019000004A1 publication Critical patent/TN2019000004A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La combinaison innovante des différents agents biologiques a permis l'élaboration d'une formule traitante sous forme de perfusion intraveineuse, pour le traitement de six (6) types de cancer qui sont : Le cancer du tissu mammaire Le cancer de l'ovaire Le cancer de la prostate Le cancer de l'estomac Le cancer de la vessie La procédure d'expérimentation était préparée durant 40 mois. L'expérimentation de la formule était réalisée en comparaison avec le traitement «cisplatine» de MYLAN et le traitement «5-fluouracile» de TEVA. Ce traitement est favorisé par rapport les autres traitements sur le marché car il assure la provocation de la procédure de la mort cellulaire des cellules cancéreuse durant une durée plus courte que la durée de la mort cellulaire en utilisant les autres formules. Aussi, la formulation de VITA provoque l'apoptose cellulaire «sélectif» sans les effets negatifs majeurs et moyens. Cette formule est destinée strictement pour l'industrie pharmaceutique.
TNP/2019/000004A 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens. TN2019000004A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TNP/2019/000004A TN2019000004A1 (fr) 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.
PCT/TN2019/000008 WO2020145905A1 (fr) 2019-01-08 2019-02-19 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TNP/2019/000004A TN2019000004A1 (fr) 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.

Publications (1)

Publication Number Publication Date
TN2019000004A1 true TN2019000004A1 (fr) 2020-07-15

Family

ID=66484117

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2019/000004A TN2019000004A1 (fr) 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.

Country Status (2)

Country Link
TN (1) TN2019000004A1 (fr)
WO (1) WO2020145905A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116575A (pt) * 2001-01-09 2004-01-06 Merck Patent Gmbh Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
WO2006012625A2 (fr) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oligonucleotides leurres stat3 et leurs utilisations
US20100150844A1 (en) * 2006-07-28 2010-06-17 The Johns Hopkins University Use of 8-quinolinol and its analogs to target cancer stem cells

Also Published As

Publication number Publication date
WO2020145905A1 (fr) 2020-07-16

Similar Documents

Publication Publication Date Title
Ito et al. The development of carcinoma in liver of rats treated with m-toluylenediamine and the synergistic and antagonistic effects with other chemicals
Banerjee et al. Efficacy of selected natural products as therapeutic agents against cancer
CN104042618B (zh) 恶性血液病的治疗
Reinhold Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies
US20210338686A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CN109906081A (zh) 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
ES2656913T3 (es) Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
Franks et al. The effect of sex hormones on the growth of HeLa tumour nodules in male and female mice
TN2019000004A1 (fr) Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.
Iwaki et al. Intra-arterial Chemotherapy With Concomitant Use of Vasoconstrictors for Liver Cancer ¹
Douple The use of platinum chemotherapy to potentiate radiotherapy
CN109419803A (zh) 细胞自噬抑制剂与阿法替尼药物组合物及其在制备肿瘤增效制剂中的用途
CN1972955B (zh) 放射增敏剂
EA014603B1 (ru) Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (варианты)
JPWO2019107341A1 (ja) オゾンナノバブルの抗がん剤
CN104640538B (zh) 包含ndga 衍生物和索拉非尼的组合物以及其在治疗癌症中的用途
CN103417554B (zh) 一种抗肿瘤的药物组合物及其应用
JPS60501408A (ja) 酸化剤ストレス誘導抗生物質に対する動物許容度を増加させる方法及び薬剤
KR20150083353A (ko) 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물
JP2021533107A (ja) 癌を治療するための併用療法
Dréau et al. Inhibitory effects of fusarochromanone on melanoma growth
Ning et al. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo
Shafik Intratunical injection of methotrexate for the treatment of seminoma of the testicle
CN108187055A (zh) 一种具有协同增效作用的抗癌组合物
CN104427988A (zh) 溶解有二氧化碳的液状药物以及采用其的治疗方法